Literature DB >> 30046161

TanCAR T cells targeting CD19 and CD133 efficiently eliminate MLL leukemic cells.

Dan Li1, Yutian Hu1, Zhen Jin1, You Zhai1, Yuting Tan1, Yan Sun1, Shouhai Zhu1, Chunjun Zhao1, Bing Chen1, Jiang Zhu1, Zhu Chen1, Saijuan Chen1, Junmin Li1, Han Liu2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30046161     DOI： 10.1038/s41375-018-0212-z

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  18 in total

Review 1.  Emerging molecular subtypes and therapeutic targets in B-cell precursor acute lymphoblastic leukemia.

Authors:  Jianfeng Li; Yuting Dai; Liang Wu; Ming Zhang; Wen Ouyang; Jinyan Huang; Saijuan Chen
Journal:  Front Med       Date:  2021-01-05       Impact factor: 4.592

Review 2.  Multi-Specific CAR Targeting to Prevent Antigen Escape.

Authors:  Zachary Walsh; Savannah Ross; Terry J Fry
Journal:  Curr Hematol Malig Rep       Date:  2019-10       Impact factor: 3.952

Review 3.  CAR T-cell immunotherapy: a powerful weapon for fighting hematological B-cell malignancies.

Authors:  Jian-Qing Mi; Jie Xu; Jianfeng Zhou; Weili Zhao; Zhu Chen; J Joseph Melenhorst; Saijuan Chen
Journal:  Front Med       Date:  2021-12-18       Impact factor: 4.592

Review 4.  Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity.

Authors:  Shengnan Yu; Ming Yi; Shuang Qin; Kongming Wu
Journal:  Mol Cancer       Date:  2019-08-20       Impact factor: 27.401

5.  CD133-directed CAR T-cells for MLL leukemia: on-target, off-tumor myeloablative toxicity.

Authors:  Clara Bueno; Talia Velasco-Hernandez; Francisco Gutiérrez-Agüera; Samanta Romina Zanetti; Matteo L Baroni; Diego Sánchez-Martínez; Oscar Molina; Adria Closa; Antonio Agraz-Doblás; Pedro Marín; Eduardo Eyras; Ignacio Varela; Pablo Menéndez
Journal:  Leukemia       Date:  2019-02-18       Impact factor: 11.528

Review 6.  Gene modification strategies for next-generation CAR T cells against solid cancers.

Authors:  Yonggui Tian; Yilu Li; Yupei Shao; Yi Zhang
Journal:  J Hematol Oncol       Date:  2020-05-18       Impact factor: 17.388

Review 7.  Programmable and multi-targeted CARs: a new breakthrough in cancer CAR-T cell therapy.

Authors:  S Tahmasebi; R Elahi; E Khosh; A Esmaeilzadeh
Journal:  Clin Transl Oncol       Date:  2020-09-30       Impact factor: 3.405

Review 8.  MLL-Rearranged Acute Leukemia with t(4;11)(q21;q23)-Current Treatment Options. Is There a Role for CAR-T Cell Therapy?

Authors:  Oliver Britten; Denise Ragusa; Sabrina Tosi; Yasser Mostafa Kamel
Journal:  Cells       Date:  2019-10-29       Impact factor: 6.600

Review 9.  Current Clinical Evidence and Potential Solutions to Increase Benefit of CAR T-Cell Therapy for Patients with Solid Tumors.

Authors:  Marion Alcantara; Pauline Du Rusquec; Emanuela Romano
Journal:  Oncoimmunology       Date:  2020-06-10       Impact factor: 8.110

10.  Restoring MLL reactivates latent tumor suppression-mediated vulnerability to proteasome inhibitors.

Authors:  Maolin Ge; Dan Li; Zhi Qiao; Yan Sun; Ting Kang; Shouhai Zhu; Shifen Wang; Hua Xiao; Chunjun Zhao; Shuhong Shen; Zhenshu Xu; Han Liu
Journal:  Oncogene       Date:  2020-07-30       Impact factor: 9.867
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.